SCHEMBL4494301

SCHEMBL4494301

CC(C)c1ccc(S(=O)(=O)NC2CNCC(C(=O)O)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 6/20 0.58
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
UCHL1 P09936 1/20 0.46
USP30 Q70CQ3 1/20 0.46
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
KCNH2 Q12809 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RECQL P46063 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NAMPT P43490 1/20 0.37
KAT6A Q92794 1/20 0.37
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494305 1.00 REN (0.58) RENALDH1A1TSHRUCHL1USP30
SCHEMBL4493885 0.86 REN (0.56) RENALDH1A1TSHRMEN1KMT2A
SCHEMBL4494691 0.86 REN (0.68) RENALDH1A1TSHRLMNAMEN1
SCHEMBL4503287 0.86 REN (0.68) RENALDH1A1TSHRLMNAMEN1
SCHEMBL4514580 0.86 REN (0.53) RENALDH1A1TSHRKDM4ERECQL
SCHEMBL4491241 0.86 REN (0.68) RENALDH1A1TSHRLMNAMEN1
SCHEMBL4493886 0.86 REN (0.56) RENALDH1A1TSHRMEN1KMT2A
SCHEMBL4494687 0.86 REN (0.68) RENALDH1A1TSHRLMNAMEN1
SCHEMBL4514576 0.86 REN (0.53) RENALDH1A1TSHRKDM4ERECQL
SCHEMBL4508089 0.84 REN (0.59) RENALDH1A1TSHRUCHL1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 REN 1/4885ALDH1A1 39/4885TSHR 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.